Aktie A2H78U PULIKE BIOLOGICAL ENGINEERING, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Pulike Biological Engineering, Inc.

Aktien

A2H78U

CNE1000025N0

603566

Schlusskurs Shanghai S.E.
Andere Börsenplätze
 00:00:00 17.04.2024 		% 5 Tage % 1. Jan.
16.95 CNY +1.62% Intraday Chart für Pulike Biological Engineering, Inc. -4.72% -25.17%
2023 Impfstoff von Pulike Biological für Atemwegserkrankungen bei Katzen besteht chinesische Notfallprüfung MT
2023 Pulike Biological Engineering, Inc. (SHSE:603566) kündigt einen Aktienrückkauf im Wert von CNY 200 Millionen an. CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Tranche Update on Pulike Biological Engineering, Inc.'s Equity Buyback Plan announced on November 14, 2023.
Tranche Update on Pulike Biological Engineering, Inc.'s Equity Buyback Plan announced on November 14, 2023.
Pulike Biological's Vaccine for Feline Respiratory Diseases Passes Chinese Emergency Evaluation
Pulike Biological Engineering, Inc. announces an Equity Buyback for CNY 120 million worth of its shares.
Pulike Biological Engineering, Inc. authorizes a Buyback Plan.
Pulike Biological Engineering, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023
Pulike Biological Engineering, Inc.(XSSC:603566) added to S&P Global BMI Index
Pulike Biological Engineering, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
Pulike Biological Engineering, Inc. agreed to acquire Luoyang Lechong Health Technology Co., Ltd. from Shiji Mengbang Information Technology Co., Ltd. and Luoyang Jidi Biotechnology Center (Limited Partnership) for CNY 23.5 million.
Pulike Biological Engineering Gets Certificate for Respiratory Drug for Chickens
Pulike Biological Engineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Pulike Biological Engineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Frontier IP investee develops vaccine candidate for Streptococcus suis
Pulike Biological Engineering, Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022
Pulike Biological Engineering Unit’s New Drug Wins Registration Certificate
Pulike Biological Engineering, Inc. announced that it has received CNY 897.999976 million in funding from a group of investors
Pulike Biological Engineering, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
CAHIC ZENAQ Animal Pharmaceutical Co., Ltd announced that it expects to receive CNY 82.72 million in funding from China Animal Husbandry Industry Co., Ltd., Pulike Biological Engineering, Inc.
Pulike Biological Engineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
Pulike Biological Engineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2H78U Aktie
  4. Nachrichten Pulike Biological Engineering, Inc.
  5. Andere Sprachen